Skip to Content

Adacel Approval History

Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)) is indicated for active booster immunization for the prevention of tetanus, diphtheria and pertussis as a single dose in persons 11 through 64 years of age.

Development History and FDA Approval Process for Adacel

Jun 10, 2005Approval Adacel Aventis Pasteur Limited - Treatment for Prevention of Tetanus, Diphtheria & Pertussis
Mar 15, 2005FDA Advisory Panel Recommends Licensure of Sanofi Pasteur's Adacel Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
Aug 11, 2004Aventis Submits Application for FDA Licensure of Adacel Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.